** Shares of drug developer Septerna SEPN.O rise 1.8% to $10.66
** Brokerage H.C. Wainwright initiates coverage with "buy" rating, sets PT at $26
** SEPN's thyroid-stimulating hormone receptor $(TSHR)$ NAM candidate and potential lead candidate in parathyroid hormone 1 receptor program could each constitute future blockbusters in niche specialty indications that provide strategic optionality - brokerage
** Novo Nordisk NOVOb.CO in May struck a $2.2 billion collaboration and licensing deal with SEPN to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases
** Brokerage believes the structure of the partnership provides significant strategic flexibility to SEPN, while eliminating clinical development and commercialization-related risk
** SEPN may have sufficient resources to fund operations beyond 2028, as Novo is committed to funding development of obesity and cardiometabolic disease-targeted candidates - Wainwright
** Up to last close, stock down 54.3% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。